NGM - NGM Biopharmaceuticals, Inc.
| Previous Close | 12.08 |
| Open | 12.15 |
| Bid | 12.44 x 1000 |
| Ask | 12.50 x 800 |
| Day's Range | 11.75 - 12.73 |
| 52 Week Range | 8.81 - 19.27 |
| Volume | 252,408 |
| Avg. Volume | 113,832 |
| Market Cap | 823.556M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.46 |
| Earnings Date | Nov 8, 2019 - Nov 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.60 |
- GlobeNewswire
NGM Bio to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2019 -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative.
- GuruFocus.com
Insiders Roundup: Facebook, Vir Biotechnology
Largest insider trades of the week Continue reading...
- American City Business Journals
Startup with eye on fatty liver disease NASH lays out $70M IPO plan
A biotech company that started in Israel 21 months ago and moved to San Francisco this year wants to raise $70 million through an initial public offering to tackle one of the hottest areas of drug development. Fourteen-employee 89bio Inc. stated in a Securities and Exchange Commission filing Friday that it plans to use the cash to complete mid-stage clinical trials of its signature drug against the fatty liver disease known as nonalcoholic steatohepatitis, or NASH, and severe hypertriglyceridemia as well as for drug manufacturing. NASH has attracted deep-pocketed drug companies such as Foster City-based Gilead Sciences Inc. (NASDAQ: GILD), South San Francisco's NGM Biopharmaceuticals Inc. (NASDAQ: NGM), Pfizer Inc. (NYSE: PFE) and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) and an army of smaller companies, such as South San Francisco's Akero Therapeutics Inc. (NASDAQ: AKRO).
- GlobeNewswire
NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH
--Treatment with aldafermin 1 mg resulted in statistically significant reductions in absolute and relative liver fat at 24 weeks compared to placebo -- -- Statistically.
- GlobeNewswire
NGM Bio to Host Conference Call to Discuss Interim Results from Ongoing 24-Week Phase 2 Study of Aldafermin (NGM282) in Patients with NASH
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2019 -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, October 7, 2019 at 8:30 a.m. ET.
- GlobeNewswire
NGM Bio Announces Multiple Aldafermin (NGM282) Poster Presentations at Upcoming AASLD’s The Liver Meeting®
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2019 -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on harnessing powerful biology to.
- Simply Wall St.
What Type Of Shareholder Owns NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM)?
If you want to know who really controls NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), then you'll have to look at the...
- Zacks
Will NGM Biopharmaceuticals Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor NGM Biopharmaceuticals.
- GlobeNewswire
NGM Bio Provides Pipeline Update and Reports Second Quarter 2019 Financial Results
--Initiated Phase 1 clinical study of NGM621 for the treatment of dry age-related macular degeneration (AMD)-- --Completed enrollment of 1 mg cohort of 24-week Phase 2 study of.
- GuruFocus.com
Weekly Top Insider Buys Highlight for the Week of July 19
The largest Insider Buys this week were for Fastenal Co., HealthEquity Inc., Hyster-Yale Materials Handling Inc. and NGM Biopharmaceuticals Inc. Continue reading...
- Simply Wall St.
How Much Are NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Insiders Spending On Buying Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- GlobeNewswire
NGM Bio to Present at Goldman Sachs 40th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 10, 2019 -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative.
- GlobeNewswire
NGM Bio to Present New Data from Phase 1b Study of NGM313 at 79th Scientific Sessions of the American Diabetes Association
SOUTH SAN FRANCISCO, Calif., June 05, 2019 -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative.
- GlobeNewswire
NGM Bio Announces Multiple Presentations at The International Liver Congress™ 2019
SOUTH SAN FRANCISCO, Calif., April 08, 2019 -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on harnessing powerful biology to.
- GlobeNewswire
NGM Bio Announces Pricing of Initial Public Offering
NGM Biopharmaceuticals, Inc. (“NGM”) today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a price to the public of $16.00 per share. In addition, NGM has granted the underwriters a 30-day option to purchase up to 1,000,000 additional shares of common stock at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market under the symbol “NGM” on April 4, 2019, and the offering is expected to close on April 8, 2019, subject to customary closing conditions.
- Benzinga
IPO Outlook For The Week: Ruhnn, Silk Road Medical, NGM Biopharmaceuticals And A Trading Platform
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Ruhnn Holding Ltd (RUHN) will issue 10 million shares between $11.50 ...
- MoneyShow
TPI Composites- Blowing in the Wind
TPI Composites (NGM) makes wind blades for wind turbines which it sells to turbine manufacturers; in fact it is the only independent manufacturer of composite wind blades for the high growth wind energy market with a global footprint, explains small cap expert Tom Bishop, editor of BI Research.
